Saturday, August 23, 2025

Mind Medicine Completes Pre-IND Meeting For LSD Assisted Therapy In Anxiety

Mind Medicine (NEO: MMED) this morning issued a brief update related two products within its research pipeline. Firstly, the company has completed a meeting with the US Food and Drug Administration in relation to its LSD assisted therapy for anxiety. And secondly, Mindmed has completed analyzing preliminary data for its 18-MC phase 1 clinical study.

In terms of its LSD assisted therapy for the treatment of anxiety, the company has concluded its pre-investigational new drug meeting with the FDA. The meeting was said to be a success, with the company indicating that it intends to file an application for a new IND with the agency in August 2021. If approved, the IND would see the company conducted a phase 2b clinical trial to evaluate the use of LSD against anxiety.

Speaking to Project Layla, which is Mind Medicine’s ibogaine-derived formulation known as 18-MC, the company is said to have completed analysis of preliminary data for the planned addiction treatment program. Both the Single Ascending Dose study as well as the Multiple Ascending Dose study have reportedly demonstrated that the drug is safe and well tolerated at the current dosages test, with no serious adverse effects.

Dose escalation is as a result expected to continue for the 18-MC trials, and upon additional data being reviewed, the company will look to initiate a Phase 2a proof of concept study. The company has indicated that a meeting with the FDA has been confirmed to discuss the development of the drug.

Mind Medicine last traded at $4.57 on the Neo Exchange.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM

MindMed Starts Clinical Trial For Intravenous DMT

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of...

Wednesday, July 28, 2021, 10:22:00 AM

Mind Medicine Sees Co-Founder Become An Activist Shareholder Demanding Changes

An activist shareholder battle might be brewing at Mind Medicine (NEO: MMED). This morning, co-founder...

Thursday, August 11, 2022, 08:41:59 AM

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to...

Wednesday, June 9, 2021, 07:50:06 AM